argenx screens cheaper on two of the three valuation measures in this snapshot. Incyte has a much lower price-to-book ratio, so the comparison doesn’t point to a clear value winner.
argenx NV ADR (ARGX) and Incyte Corporation (INCY) are both in the Health Care sector’s Pharmaceuticals, Biotechnology & Life Sciences group. At the latest adjusted close on 2026-11-03, ARGX traded at US$901.12 per share, with a market cap of US$55.0B. INCY traded at US$117.59 per share, with a market cap of US$24.5B. Share prices alone don’t show which company is cheaper. Valuation multiples offer a more useful comparison, though they tell only part of the story.
Investor takeaway: ARGX has the lower P/E and PEG, while INCY has the lower P/B. ARGX screens cheaper on two of the three measures, but that doesn’t prove it’s undervalued or the better investment. The ratios don’t capture all differences in growth expectations, business risks or financial performance.
Stocks in this list
Live snapshots — open any name for the full quote and Wealth Awesome price forecast.
argenx NV ADR
ARGX.US
Health Care
$901.12
$55.02B
1D
+2.99%
1W
+2.11%
Incyte Corporation
INCY.US
Health Care
$117.59
$24.47B
1D
-2.04%
1W
+0.85%
Two multiples favour ARGX; one favours INCY
ARGX’s P/E is 30.3, compared with 61.2 for INCY. Its PEG is 1.20, compared with 10.82. But INCY’s P/B of 4.25 is far below ARGX’s 167.38. The results are mixed, even though ARGX has the lower figure on two of the three measures.
Bull case
ARGX has a lower P/E and PEG than INCY: 30.3 versus 61.2, and 1.20 versus 10.82. Its reported TTM ROE is also higher, at 23.6% compared with INCY’s 7.8%. These figures may be worth looking into, but they don’t settle whether ARGX is fairly valued.
Bear case
ARGX’s P/B of 167.38 is far higher than INCY’s 4.25, making INCY look cheaper on this measure. That difference complicates the case for calling ARGX the cheaper stock. This snapshot doesn’t explain the gap or show what either company is worth.
The valuation table is split
ARGX has the lower P/E and PEG: 30.3 compared with INCY’s 61.2, and 1.20 compared with 10.82. The P/B tells a different story. INCY’s 4.25 is well below ARGX’s 167.38. So ARGX has the lower multiple on two of the three measures, but the comparison is still mixed and doesn’t identify a clear value winner.
| Measure | ARGX | INCY | Lower multiple |
|---|---|---|---|
| P/E | 30.3 | 61.2 | ARGX |
| PEG | 1.20 | 10.82 | ARGX |
| P/B | 167.38 | 4.25 | INCY |
For more company-specific information, see the argenx stock page and the Incyte stock page.
What the snapshot adds, and what it leaves open
The latest adjusted closes, dated 2026-11-03, were US$901.12 for ARGX and US$117.59 for INCY. Their market caps were US$55.0B and US$24.5B, respectively. Both reported a 0.00% dividend yield. ARGX’s TTM ROE was 23.6%, compared with 7.8% for INCY. The supplied analyst consensus is Buy for both, with listed targets of US$1,147.35 for ARGX and US$131.08 for INCY. These figures are a snapshot, not a promise of future performance.
Multiples are one way to compare companies, but they don’t show whether a lower figure is a bargain. They also don’t explain the large gap in P/B or account for every company-specific risk and expectation. If you’re considering either stock, look at its business, financial statements and risks alongside these figures.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
